Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has...
Vaccine
Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults
Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...
Clover Bio’s SCB-1019 Vaccine Candidate Shows Promising Results in Phase I Trial
Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary...
Walvax Biotechnology’s COVID-19 Variant Vaccine RQ3033 Shows Positive Phase III Results
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III...
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...
CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia
China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study...
Beijing Varnotech Biopharm Secures RMB 600 Million in Series B Funding for Vaccine Development
Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600...
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...
European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use
The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...
Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...
GSK Reports US Adult Non-Flu Vaccination Rates Recover Post-Pandemic
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that...
AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study
AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development...
Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results
Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based...
CanSino Biologics’ 13-Valent Pneumococcal Vaccine CRM197 Accepted for NMPA Review
CanSino Biologics Inc., (HKG: 6185), a leading Chinese biopharmaceutical company, has announced that the National...
Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights
Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of...
Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal
Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI...
FDA Grants Priority Review for GSK’s Arexvy to Expand RSV Vaccine Age Range to 50-59
The U.S. Food and Drug Administration (FDA) has initiated a priority review of GlaxoSmithKline’s (GSK;...
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...